Press "Enter" to skip to content

European Medicines Agency: Benefits of AstraZeneca vaccine outweigh risks

The European Medicines Agency (EMA), the European Union’s (EU) drug regulator, reported that the benefits of the Covid-19 vaccine AstraZeneca, which was discontinued in some European countries on the grounds that it causes blood clotting, outweighed the risks.

EMA, which gathered to determine opinion after the use of the Covid-19 vaccine developed by AstraZeneca, was stopped in some countries, made a statement on the subject.

In the statement, it was reported that the AstraZeneca vaccine, which was suspended for precautionary purposes in some European countries such as France, Germany, Italy and the Netherlands, continued to be examined on the grounds that it could cause blood clotting and death.

It was stated that the coagulation cases were expressed in very small numbers, “The number of cases of vascular occlusion due to coagulation in vaccinated people does not appear to be more than those found in the general population.”

It was stated that investigations will continue to determine whether the vaccine caused the problems in the cases in question and that a conclusion would be reached on Thursday in the light of the information obtained.

The statement said, “While the review is ongoing, the EMA maintains the view that the benefit of AstraZeneca vaccine in preventing Covid-19 in connection with hospitalizations and deaths outweighs the risks of side effects.”

World Health Organization (WHO) experts also made the statement that “There are no documented deaths associated with Covid-19 vaccines after more than 300 million doses of different vaccines have been administered worldwide” and called on people who use AstraZeneca and other vaccines “not to panic”.

In European countries, 22 of the 3 million people who received the AstraZeneca vaccine as of 9 March had coagulation cases.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *